Details

Autor(en) / Beteiligte

• Mitnick, Carole D
• Shin, Sonya S
• Seung, Kwonjune J
• Rich, Michael L
• Atwood, Sidney S
• Furin, Jennifer J
• Fitzmaurice, Garrett M
• Alcantara Viru, Felix A
• Appleton, Sasha C
• Bayona, Jaime N
• Bonilla, Cesar A
• Chalco, Katiuska
• Choi, Sharon
• Franke, Molly F
• Fraser, Hamish S.F
• Guerra, Dalia
• Hurtado, Rocio M
• Jazayeri, Darius
• Joseph, Keith
• Llaro, Karim
• Mestanza, Lorena
• Mukherjee, Joia S
• Muñoz, Maribel
• Palacios, Eda
• Sanchez, Epifanio
• Sloutsky, Alexander
• Becerra, Mercedes C

Titel

Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis

Ist Teil von

• The New England journal of medicine, 2008-08, Vol.359 (6), p.563-574

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2008

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Important questions exist regarding the ability to treat extensively drug-resistant tuberculosis. In this study involving 48 patients in Peru who had extensively drug-resistant tuberculosis but were not infected with the human immunodeficiency virus, treatment with a structured, comprehensive, community-based approach and aggressive antituberculosis medications (an average of five or six medications per patient) achieved a cure in 29 patients (60%). In 48 patients in Peru who had extensively drug-resistant tuberculosis, treatment with a structured, comprehensive, community-based approach and aggressive antituberculosis medications achieved a cure in 29 patients (60%). Extensively drug-resistant tuberculosis has been reported in 45 countries 1 since it was first described in 2006. This seminal survey found extensively drug-resistant tuberculosis — then defined as Mycobacterium tuberculosis strains with resistance to at least isoniazid, rifampin, and members of three of six classes of second-line drugs — in 10% of multidrug-resistant tuberculosis strains collected on six continents. 2 Isoniazid and rifampin are the anchors of standard first-line therapy. 3 Resistance to these two drugs, which defines multidrug-resistant tuberculosis, is associated with a decreased probability of cure. 4 – 6 Treatment regimens for multidrug-resistant tuberculosis rely on the most active second-line drug classes — . . .